| Old Articles: <Older 17421-17430 Newer> |
|---|
 |
The Motley Fool
October 16, 2006
Tim Beyers |
IRS to Tax Your Second Life? Congressional economists are beginning to weigh the question of how to tax digital assets amassed in multiplayer online games such as World of Warcraft and Second Life. How can this benefit your portfolio?   |
The Motley Fool
October 16, 2006
Brian Lawler |
The Coming Generic Drug Boom Generic drugmakers are poised to profit from several key factors. Investors, take note. |
The Motley Fool
October 16, 2006
Anders Bylund |
3 Stocks That Missed the Mark A peek at companies that over-promised and under-delivered. Emmis Communications... Banco Popular... Alcoa... |
The Motley Fool
October 16, 2006
Alyce Lomax |
All Eyes on CBS CBS teams with Yahoo! to distribute local video news online. Investors might want to reserve their optimism until they've got more proof that CBS's digital strategies are working. |
The Motley Fool
October 16, 2006
David Lee Smith |
Cablevision Almost Gone The Dolan family's latest Cablevision buyout offer appears likely to succeed. Investors, take note. |
The Motley Fool
October 16, 2006
S.J. Caplan |
Scouting the Latest IPOs An investor's roundup of new-issue hits, misses, and no-shows. Acme Packet... eHealth... Science Applications International... UltraPetrol Bahamas... etc. |
The Motley Fool
October 16, 2006
Brian Gorman |
Oshkosh Snags JLG Oshkosh's purchase of JLG should help keep the specialty truck maker firing on all cylinders. Investors, take note. |
The Motley Fool
October 16, 2006
Rick Aristotle Munarriz |
Heavy Mattel Mattel has a better-than-expected showing as it heads into the holidays. Investors, take note. |
The Motley Fool
October 16, 2006
Ryan Fuhrmann |
Juiced Results at Pepsico Currently, Pepsi's valuation is a bit too high, as it will have to post many more years of double-digit growth to justify the current stock price. |
The Motley Fool
October 16, 2006
Alyce Lomax |
Bad Medicine for Liz Claiborne? Is Liz Claiborne crazy to hire a J&J exec as CEO? Is this bad medicine for Liz Claiborne investors? Maybe this move's not as crazy as it seems. |
| <Older 17421-17430 Newer> Return to current articles. |
